Korea Exchange · Healthcare
ORIENT BIO stock from India: price, numbers and tax
ORIENT BIO (002630) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
ORIENT BIO at a glance
- Price
- ₩1,638.00-₩21.00 (1.27%)
- Market cap
- ₩48.56B
- Day range
- ₩1,631.00 – ₩1,690.00
- P/E
- 21.01
- Dividend yield
- None
- Volume
- 19.51K
- 1 month
- -10.30%
- 6 months
- -25.14%
- YTD
- -31.86%
- 1 year
- -29.15%
- 5 years
- -70.54%
ORIENT BIO statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩29.8B | ₩29.4B | ₩28.0B | ₩28.8B | ₩26.3B |
| Gross profit | ₩4.0B | ₩7.2B | ₩9.6B | ₩9.8B | ₩9.0B |
| Operating income | −₩4.4B | −₩3.1B | −₩645.9M | ₩1.5B | −₩3.8B |
| Net income | −₩4.6B | −₩13.2B | ₩12.9B | −₩12.4B | ₩34.2B |
| Earnings per share | −₩154.06 | −₩445.14 | ₩434.22 | −₩419.12 | −₩52.58 |
| EBITDA | −₩2.2B | −₩11.0B | ₩15.7B | −₩9.2B | ₩997.2M |
| Total assets | ₩81.6B | ₩84.8B | ₩97.0B | ₩81.1B | ₩105.0B |
| Total debt | ₩1.9B | ₩2.6B | ₩3.0B | ₩847.8M | ₩7.4B |
| Cash and short-term investments | ₩32.8B | ₩32.5B | ₩41.2B | ₩35.5B | ₩59.0B |
| Shareholders' equity | ₩68.5B | ₩71.8B | ₩85.1B | ₩71.4B | ₩83.2B |
| Operating cash flow | ₩2.6B | ₩752.3M | ₩3.8B | ₩1.2B | ₩2.4B |
| Free cash flow | ₩547.9M | −₩4.0B | ₩2.8B | ₩674.3M | ₩140.5M |
| Capital expenditure | −₩2.0B | −₩4.8B | −₩925.3M | −₩485.6M | −₩2.2B |
Fiscal years as reported, the latest ending 31 Mar 2026. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Ray | 228670.KQ | ₩4,475.00 | ₩69.82B |
| PharmGen Science | 004720.KS | ₩2,860.00 | ₩62.67B |
| Yuyu Pharma | 000220.KS | ₩3,840.00 | ₩60.47B |
| Yuyu Pharma | 000225.KS | ₩3,605.00 | ₩56.77B |
| Yuyu Pharma | 000227.KS | ₩7,980.00 | ₩46.76B |
| IVIM Technology | 460470.KQ | ₩3,025.00 | ₩45.74B |
| MYUNGMOON Pharm | 017180.KS | ₩1,286.00 | ₩42.99B |
| Hass | 450330.KQ | ₩4,815.00 | ₩37.72B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in ORIENT BIO from India
What ORIENT BIO does
ORIENT BIO Inc. is a South Korean company active within the biotechnology sector. The firm specializes in providing laboratory animals and a range of equipment tailored for research environments. ORIENT BIO operates in the Biotechnology industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell ORIENT BIO shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.